BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND STAT5B, STAT5, 6777, ENSG00000173757, P51692 AND Prognosis
85 results:

  • 1. Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations.
    Wang Z; Lu X; Liu C; Huang F; Lu T; Chen Y; Liu L; Lu S
    Eur J Med Chem; 2024 Mar; 268():116237. PubMed ID: 38387337
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/stat5 signalling pathways and sensitivity to TKI in ph-like ALL.
    Xu GF; Zeng Z; Zhang ZB; Zhang XM; Wang M; Xiao Q; Li J; Xie XQ; He S; Fu HH; Liu Y; Yang ZL; Chen Y; Shi J; Wang B; Qiu HY; Zhou Q; Liu Y; Chen SN
    J Cell Mol Med; 2024 Feb; 28(3):e18114. PubMed ID: 38323741
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Targeting of stat5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression.
    Li J; Tang B; Miao Y; Li G; Sun Z
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37830151
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. XBP1 promotes NRAS
    Salimi A; Schemionek-Reinders M; Huber M; Vieri M; Patterson JB; Alten J; Brümmendorf TH; Kharabi Masouleh B; Appelmann I
    J Cell Mol Med; 2023 Nov; 27(21):3363-3377. PubMed ID: 37753803
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. A novel lncRNA SNHG29 regulates EP300- related histone acetylation modification and inhibits FLT3-ITD AML development.
    Liu S; Zhou J; Ye X; Chen D; Chen W; Lin Y; Chen Z; Chen B; Shang J
    Leukemia; 2023 Jul; 37(7):1421-1434. PubMed ID: 37157016
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of
    Wu S; Edwards H; Wang D; Liu S; Qiao X; Carter J; Wang Y; Taub JW; Wang G; Ge Y
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078163
    [No Abstract]    [Full Text] [Related]  

  • 7. The nature inspired peptide [T20K]-kalata B1 induces anti-tumor effects in anaplastic large cell lymphoma.
    Lind J; Hellinger R; Kudweis P; Moll HP; Gattringer J; Thell K; Edtmayer S; Gruber CW; Stoiber D; Kollmann K
    Biomed Pharmacother; 2022 Sep; 153():113486. PubMed ID: 36076504
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Recent research on the association between signal transducer and activator of transcription 5 and childhood acute lymphoblastic leukemia.
    Duan YF; Wen FQ
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Aug; 24(8):942-947. PubMed ID: 36036135
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
    Chiriches C; Khan D; Wieske M; Guillen N; Rokicki M; Guy C; Wilson M; Heesom KJ; Ottmann OG; Ruthardt M
    Ann Hematol; 2022 Oct; 101(10):2179-2193. PubMed ID: 35941390
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid leukemia.
    Takeda J; Yoshida K; Nakagawa MM; Nannya Y; Yoda A; Saiki R; Ochi Y; Zhao L; Okuda R; Qi X; Mori T; Kon A; Chiba K; Tanaka H; Shiraishi Y; Kuo MC; Kerr CM; Nagata Y; Morishita D; Hiramoto N; Hangaishi A; Nakazawa H; Ishiyama K; Miyano S; Chiba S; Miyazaki Y; Kitano T; Usuki K; Sezaki N; Tsurumi H; Miyawaki S; Maciejewski JP; Ishikawa T; Ohyashiki K; Ganser A; Heuser M; Thol F; Shih LY; Takaori-Kondo A; Makishima H; Ogawa S
    Blood Cancer Discov; 2022 Sep; 3(5):410-427. PubMed ID: 35839275
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma.
    Tang X; Yang ZZ; Kim HJ; Anagnostou T; Yu Y; Wu X; Chen J; Krull JE; Wenzl K; Mondello P; Bhardwaj V; Wang J; Novak AJ; Ansell SM
    Clin Cancer Res; 2022 Oct; 28(19):4322-4335. PubMed ID: 35686915
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid leukemia with Adverse Genetic Factors.
    Ikeda D; Chi S; Uchiyama S; Nakamura H; Guo YM; Yamauchi N; Yuda J; Minami Y
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682627
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo.
    Spohr C; Poggio T; Andrieux G; Schönberger K; Cabezas-Wallscheid N; Boerries M; Halbach S; Illert AL; Brummer T
    Leukemia; 2022 Apr; 36(4):970-982. PubMed ID: 34903841
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia.
    Xu S; Zhang M; Fang X; Meng J; Xing H; Yan D; Liu J; Yang Y; Wen T; Zhang W; Wang J; Wang C; Xu H
    J Hematol Oncol; 2021 Nov; 14(1):193. PubMed ID: 34774070
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML.
    Charlet A; Kappenstein M; Keye P; Kläsener K; Endres C; Poggio T; Gorantla SP; Kreutmair S; Sänger J; Illert AL; Miething C; Reth M; Duyster J; Rummelt C; von Bubnoff N
    Leukemia; 2022 Mar; 36(3):701-711. PubMed ID: 34750506
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. GATM-Mediated Creatine Biosynthesis Enables Maintenance of FLT3-ITD-Mutant Acute Myeloid leukemia.
    Zhang Y; Newsom KJ; Zhang M; Kelley JS; Starostik P
    Mol Cancer Res; 2022 Feb; 20(2):293-304. PubMed ID: 34635505
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways.
    Pulikkottil AJ; Bamezai S; Ammer T; Mohr F; Feder K; Vegi NM; Mandal T; Kohlhofer U; Quintanilla-Martinez L; Sinha A; Buske C; Rawat VPS
    Leukemia; 2022 Feb; 36(2):416-425. PubMed ID: 34462525
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells.
    Liu Z; Zheng W; Liu Y; Zhou B; Zhang Y; Wang F
    Exp Cell Res; 2021 Aug; 405(2):112708. PubMed ID: 34157313
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Therapeutic delivery of siRNA with polymeric carriers to down-regulate stat5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL).
    Mohseni M; Kucharski C; K C RB; Nasrullah M; Jiang X; Uludağ H; Brandwein J
    PLoS One; 2021; 16(6):e0251719. PubMed ID: 34157051
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression.
    Lv K; Ren JG; Han X; Gui J; Gong C; Tong W
    Blood; 2021 Dec; 138(22):2244-2255. PubMed ID: 34111291
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.